Umoja Biopharma to Present at the 9th Annual CAR-TCR Summit

SEATTLE, Sept. 11, 2024 (GLOBE NEWSWIRE) — Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in oncology and autoimmunity, today announced that Ryan Crisman, Ph.D., Co-Founder and Chief Technical Officer of Umoja, will present on the growing promise of Umoja’s in vivo clinical-stage science and manufacturing strategy at the 9^th Annual CAR-TCR Summit being held September 17-20, 2024, in Boston, Massachusetts.

Details of the presentations can be found below:

Format: Company Presentation
Title: The Make vs Buy Decision for Early Stage Biotechs in the Cell & Gene Therapy Space: Umoja Biopharma’s Experience
Track: Supply Chain & Clinical Operations Track
Date: Wednesday, September 18, 2024
Time: 11:40 am ET

Format: Panel Discussion
Title: Highlighting the Next Generation Opportunity & Potential for In Vivo Engineered Cell Therapies
Track: Discovery Track
Date: Thursday, September 19, 2024
Time: 12:25 pm ET

About Umoja Biopharma
Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR-T cell therapies in both oncology and autoimmunity. Umoja’s VivoVec™ in vivo gene delivery technology empowers a patient’s own immune system to fight disease. Enabling its core technology is the Company’s state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with Umoja on LinkedIn and visit http://umoja-biopharma.com/.

Investors
Stephen Jasper
Gilmartin Group, LLC
[email protected]

Media  
Matt Wright
Real Chemistry
[email protected]

• Author
• Recent Posts

GlobeNewswire

GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Latest posts by GlobeNewswire (see all)

• Osisko Development to Close Second Tranche of Non-Brokered Private Placement of Units - October 7, 2024
• Iris Energy Limited Investors: Please contact the Portnoy Law Firm to recover your losses. December 6, 2024 Deadline to file Lead Plaintiff Motion - October 7, 2024
• Visa Inc. Investors: Company Investigated by the Portnoy Law Firm - October 7, 2024